U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like ...

Eli Lilly and Company reported third quarter ... I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no ...

Sales growth should continue as the company increases production and looks to win approvals for indications covered by Medicare. The stock looks attractively valued at current prices. Eli Lilly ...

Powered by its popular GLP-1 weight loss drugs, Eli Lilly's stock (NYSE: LLY) has had a strong run this year, up more than 55%. However, the company's success goes back much further, with the ...

Thanks for joining us for Eli Lilly and Company's Q3 2024 earnings call ... which of the 12 different dosage forms they want to stock and at what level. There are some physical constraints ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss ... figures well below analysts’ expectations. This led to the company’s stock falling more than 13% in Wednesday morning trading.

Bernstein initiated coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Finally ...